Novartis and Unnatural Products Ink $1.8 Billion Cardiovascular Deal

The agreement provides Unnatural Products with an initial $100 million in upfront payments and pre-investigational new drug (IND) milestones. Beyond the initial phase, the California-based biotech remains eligible for an additional $1.7 billion contingent on reaching specific development, regulatory, and commercial benchmarks. While the specific program remains undisclosed, the collaboration focuses on the high-stakes field of cardiovascular disease.

The Path to Commercialization

Under the terms of the deal, Unnatural Products will deploy its AI-enhanced discovery engine to identify viable macrocycle candidates. Once identified, Novartis will assume full responsibility for IND-enabling studies, clinical trials, manufacturing, and global commercialization. This structure allows the biotech to focus on its computational strengths while leveraging the Swiss drugmaker's extensive infrastructure.

"Novartis has built a highly respected engine in cardiovascular innovation," stated Cameron Pye, Chief Executive of Unnatural Products. He noted that the collaboration is designed to "unlock the full therapeutic potential" of the asset. The move signals a continued industry trend of major pharmaceutical players investing heavily in AI-driven platforms to shorten the discovery timeline for previously inaccessible biological targets.